Fluidigm
Fluidigm Q1 Revenues Grow 19 Percent
The firm adjusted its 2021 revenue guidance range downward due to COVID-19 testing uncertainty, partially offset by expected growth in its core omics tools business.
DARPA program managers said they are developing different testing modalities that are crucially linked in their objective to facilitate more comprehensive and faster testing.
FDA Reissues EUA for Fluidigm SARS-CoV-2 Test for Use With Azova Home Collection Kit
Azova's kit is for use with Fluidigm's Advanta Dx SARS-CoV-2 RT-PCR assay, an extraction-free, saliva-based COVID test that previously received EUA.
Fluidigm CEO Chris Linthwaite said the company aims to further penetrate the diagnostic and clinical markets with both its microfluidics and mass cytometry businesses.
Fluidigm Q4 Revenues Grow 38 Percent on COVID-19-Driven Microfluidics Growth
The firm also announced a COVID-19 testing deal with George Mason University and a CyTOF supply and distribution agreement with Zhejiang PuLuoTing Health Technology in China.